Holen Sie sich die Stockscreener-App
22.74
4.17%
0.91
Handel nachbörslich:
22.74
Schlusskurs vom Vortag:
$21.83
Offen:
$22.03
24-Stunden-Volumen:
808.30K
Relative Volume:
0.55
Marktkapitalisierung:
$2.82B
Einnahmen:
$376.07M
Nettoeinkommen (Verlust:
$-16.14M
KGV:
-162.54
EPS:
-0.1399
Netto-Cashflow:
$-16.31M
1W Leistung:
+2.25%
1M Leistung:
-15.81%
6M Leistung:
+35.92%
1J Leistung:
+32.90%
1-Tages-Spanne:
$21.95
$23.00
1-Wochen-Bereich:
$21.57
$23.46
52-Wochen-Spanne:
$11.86
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Firmenname
Arcutis Biotherapeutics Inc
Sektor
Branche
Telefon
805-418-5006
Adresse
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
22.74 | 2.71B | 376.07M | -16.14M | -16.31M | -0.1399 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Eingeleitet | Goldman | Neutral |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-10-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-09-07 | Eingeleitet | Needham | Buy |
| 2022-03-17 | Eingeleitet | Goldman | Buy |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-05-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Hochstufung | Goldman | Neutral → Buy |
| 2020-10-08 | Eingeleitet | Truist | Buy |
| 2020-02-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Eingeleitet | Cowen | Outperform |
| 2020-02-25 | Eingeleitet | Goldman | Neutral |
| 2020-02-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children - MSN
Understanding the Setup: (ARQT) and Scalable Risk - Stock Traders Daily
Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data - Yahoo Finance
Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children - Insider Monkey
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - Bitget
Arcutis Biotherapeutics (ARQT) Unveils New Trial Data at Dermato - GuruFocus
New eczema treatment data in infants and kids set for 2026 AAD - Stock Titan
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE Cream - MSN
Fundamentals Check: Can Arcutis Biotherapeutics Inc stock outperform in a bear market2026 PostEarnings & Risk Managed Trade Strategies - baoquankhu1.vn
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? - MSN
Ally Bridge Group NY LLC Invests $4.40 Million in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics, Inc. $ARQT Stock Holdings Lessened by Suvretta Capital Management LLC - MarketBeat
Stock Recap: Can Arcutis Biotherapeutics Inc sustain earnings growth2026 WrapUp & Expert-Curated Trade Recommendations - baoquankhu1.vn
The Technical Signals Behind (ARQT) That Institutions Follow - Stock Traders Daily
Arcutis reports long-term data on eczema cream for young children - Investing.com Canada
Arcutis reports long-term data on eczema cream for young children By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics (ARQT) Reports Positive Findings from Zo - GuruFocus
Jefferies Remains a Buy on Arcutis Biotherapeutics (ARQT) - The Globe and Mail
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology - The Manila Times
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology - Bitget
Year-long eczema study: Arcutis cream eased symptoms in young kids - Stock Titan
ARQT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline - TipRanks
Arcutis (ARQT) Q4 2025 Earnings Call Transcript - AOL.com
Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating - Yahoo Finance
GW&K Investment Management LLC Sells 206,391 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
10 Fastest Growing NASDAQ Stocks to Buy - Insider Monkey
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth - Sahm
Arcutis Promotes Mas Matsuda to Executive Vice President, Chief Legal Officer - Contract Pharma
Mas Matsuda Promoted to Executive Vice President and Chief Legal Officer at Arcutis Biotherapeutics - geneonline.com
Arcutis Biotherapeutics (ARQT) Elevates Legal Leader to Executiv - GuruFocus
Arcutis Biotherapeutics Promotes Mas Matsuda to Executive Vice President and Chief Legal Officer - Quiver Quantitative
ARQT SEC FilingsArcutis Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Arcutis (ARQT) Earnings Call Signals Scaled Growth - TipRanks
Insider Sell Alert: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus
Arcutis Biotherapeutics Director Sells Shares - TradingView
Arcutis (ARQT) director sells 39,272 shares under 10b5-1 plan - Stock Titan
Vanguard Group Inc. Buys 96,991 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 3,687 Shares - MarketBeat
Masaru Matsuda Sells 3,325 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Masaru Matsuda Sells 8,733 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Patrick Burnett Sells 6,287 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 37,349 Shares of Stock - MarketBeat
Arcutis (ARQT) officer sells 3,687 shares and receives major equity grants - Stock Titan
Arcutis (ARQT) director Watanabe sells shares and receives large option, RSU awards - Stock Titan
Arcutis enrolls first patient in ARQ-234 atopic dermatitis trial By Investing.com - Investing.com Australia
A Look At Arcutis Biotherapeutics (ARQT) Valuation After New Trial Launch And Upgraded Revenue Outlook - simplywall.st
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis - Bitget
Arcutis Biotherapeutics Begins Enrollment for Phase 1a/1b Atopic Dermatitis Study - marketscreener.com
Finanzdaten der Arcutis Biotherapeutics Inc-Aktie (ARQT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):